'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research'.
Maria Ilenia PassalacquaGraziella RizzoMariacarmela SantarpiaGiuseppe CuriglianoPublished in: Expert opinion on investigational drugs (2022)
The complexity of TNBC is not only the main reason of its aggressivity, but its heterogeneity should be exploited in terms of therapeutics opportunities, combining agents with different mechanism of action, after a correct selection by biologic or molecular biomarkers. The main goal is to understand what TNBC really is and to act selectively on its characteristics, with a personalized anticancer treatment.